Literature DB >> 11182759

Prevalence of Gs alpha mutations in Korean patients with pituitary adenomas.

H J Kim1, M S Kim, Y J Park, S W Kim, D J Park, K S Park, S Y Kim, B Y Cho, H K Lee, H W Jung, D H Han, H S Lee, J G Chi.   

Abstract

The reported frequencies of Gs alpha mutations (gsp mutations) in growth hormone (GH)-secreting pituitary adenomas are variable (ranging from 4.4 to 43%), and the presence of these mutations in the other pituitary adenomas is still a matter of controversy. Previous clinical and biochemical analyses of patients with GH-secreting pituitary adenomas and gsp mutations produced conflicting results and did not demonstrate obvious characteristics. Therefore, we investigated the prevalence of gsp mutations in Korean patients with pituitary adenomas and elucidated the characteristics of these patients. Forty-four GH-secreting adenomas, 7 prolactin (PRL)-secreting adenomas and 32 clinically non-functioning adenomas were examined for the presence of point mutations in codon 201 and 227 of the Gs alpha gene using a nested PCR and direct sequencing of DNA extracted from fresh tissue or paraffin-embedded pituitary adenoma samples. Seven of the 44 GH-secreting pituitary adenomas had point mutations at codon 201 or 227; of these, five mutations were in codon 201 and two were in codon 227. In patients with gsp mutations, mean tumor size was significantly smaller than in patients without gsp mutations (15.9+/-8.7 mm vs. 24.9+/-14.9 mm, P<0.05). Age, sex, basal GH levels, GH response to oral glucose loading, GH response to octreotide and surgical outcome were not different in the two groups. One of the 32 clinically non-functioning pituitary adenomas had a point mutation at codon 201; none of the seven prolactinomas had these mutations. These results show that gsp mutations are not rare in Korean acromegalic patients and mean tumor size is significantly smaller in acromegalic patients with gsp mutations. Our results also confirm the low frequency of gsp mutations in clinically non-functioning pituitary adenomas and the absence of gsp mutations in prolactinoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11182759     DOI: 10.1677/joe.0.1680221

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  7 in total

1.  Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis.

Authors:  Z A Efstathiadou; A Bargiota; A Chrisoulidou; G Kanakis; L Papanastasiou; A Theodoropoulou; S K Tigas; D A Vassiliadi; M Alevizaki; S Tsagarakis
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

2.  Analysis of GNAS mutations in 60 growth hormone secreting pituitary tumors: correlation with clinical and pathological characteristics and surgical outcome based on highly sensitive GH and IGF-I criteria for remission.

Authors:  Pamela U Freda; Wendy K Chung; Naoki Matsuoka; Jane E Walsh; M Nabi Kanibir; George Kleinman; Yuanjia Wang; Jeffrey N Bruce; Kalmon D Post
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

3.  Prevalence of gsp oncogene in somatotropinomas and clinically non-functioning pituitary adenomas: our experience.

Authors:  Giselle Fernandes Taboada; Ana Lúcia Osório Tabet; Luciana A Naves; Denise Pires de Carvalho; Mônica Roberto Gadelha
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

4.  Genetic analysis of a patient with coexisting acromegaly, thyroid papillary carcinoma and subcutaneous fibroma.

Authors:  Jingfang Liu; Xulei Tang; Jianguo Cheng; Liting Wang; Xiaomei Yang; Yan Wang
Journal:  Oncol Lett       Date:  2014-12-23       Impact factor: 2.967

Review 5.  Genetic and Epigenetic Pathogenesis of Acromegaly.

Authors:  Masaaki Yamamoto; Yutaka Takahashi
Journal:  Cancers (Basel)       Date:  2022-08-10       Impact factor: 6.575

6.  A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly.

Authors:  Moises Mercado; Fatima Borges; Hakim Bouterfa; Tien-Chun Chang; Alberto Chervin; Andrew J Farrall; Attila Patocs; Stephan Petersenn; Jan Podoba; Mitra Safari; Joanna Wardlaw
Journal:  Clin Endocrinol (Oxf)       Date:  2007-04-25       Impact factor: 3.478

7.  The curious case of Gαs gain-of-function in neoplasia.

Authors:  Giulio Innamorati; Thomas M Wilkie; Havish S Kantheti; Maria Teresa Valenti; Luca Dalle Carbonare; Luca Giacomello; Marco Parenti; Davide Melisi; Claudio Bassi
Journal:  BMC Cancer       Date:  2018-03-15       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.